Institute for Neuro-Immune Medicine, Nova Southeastern University, Ft. Lauderdale, FL, USA; College of Psychology, Nova Southeastern University, Ft. Lauderdale, FL, USA.
Institute for Neuro-Immune Medicine, Nova Southeastern University, Ft. Lauderdale, FL, USA; Department of Clinical Immunology, Nova Southeastern University, Ft. Lauderdale, FL, USA.
Clin Ther. 2019 May;41(5):815-835.e6. doi: 10.1016/j.clinthera.2019.01.011. Epub 2019 Mar 6.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisymptom illness impacting up to 1 million people in the United States. As the pathogenesis and etiology of this complex condition are unclear, prospective treatments are limited. Identifying US Food and Drug Administration-approved drugs that may be repositioned as treatments for ME/CFS may offer a rapid and cost-effective solution.
Here we used gene-expression data from 33 patients with Fukuda-defined ME/CFS (23 females, 10 males) and 21 healthy demographically comparable controls (15 females, 6 males) to identify differential expression of predefined gene-module sets based on nonparametric statistics. Differentially expressed gene modules were then annotated via over-representation analysis using the Consensus Pathway database. Differentially expressed modules were then regressed onto measures of fatigue and cross-referenced with drug atlas and pharmacogenomics databases to identify putative treatment agents.
The top 1% of modules identified in males indicated small effect sizes in modules associated with immune regulation and mitochondrial dysfunction. In females, modules identified included those related to immune factors and cardiac/blood factors, returning effect sizes ranging from very small to intermediate (0.147 < Cohen δ < 0.532). Regression analysis indicated that B-cell receptors, T-cell receptors, tumor necrosis factor α, transforming growth factor β, and metabolic and cardiac modules were strongly correlated with multiple composite measures of fatigue. Cross-referencing identified genes with pharmacogenomics data indicated immunosuppressants as potential treatments of ME/CFS symptoms.
The findings from our analysis suggest that ME/CFS symptoms are perpetuated by immune dysregulation that may be approached via immune modulation-based treatment strategies.
肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)是一种使人虚弱的多症状疾病,影响美国多达 100 万人。由于这种复杂疾病的发病机制和病因尚不清楚,因此前瞻性治疗方法有限。确定美国食品和药物管理局批准的可能重新定位为 ME/CFS 治疗药物的药物可能提供一种快速且具有成本效益的解决方案。
在这里,我们使用了来自 33 名福冈定义的 ME/CFS 患者(23 名女性,10 名男性)和 21 名健康的人口统计学可比对照者(15 名女性,6 名男性)的基因表达数据,根据非参数统计数据确定预先定义的基因模块集的差异表达。然后使用 Consensus Pathway 数据库通过过度表达分析对差异表达的基因模块进行注释。然后将差异表达的模块回归到疲劳测量值上,并与药物图谱和药物基因组学数据库进行交叉引用,以确定潜在的治疗剂。
在男性中,前 1%的模块确定了与免疫调节和线粒体功能障碍相关的模块的小效应大小。在女性中,确定的模块包括与免疫因子和心脏/血液因子相关的模块,其返回的效应大小从非常小到中等(0.147<Cohen δ<0.532)。回归分析表明,B 细胞受体、T 细胞受体、肿瘤坏死因子 α、转化生长因子 β 以及代谢和心脏模块与多种疲劳综合测量值强烈相关。与药物基因组学数据的交叉引用确定了免疫抑制剂是 ME/CFS 症状的潜在治疗药物。
我们分析的结果表明,ME/CFS 症状是由免疫失调引起的,这种失调可能通过基于免疫调节的治疗策略来解决。